Hurthle Cell Carcinoma: Multimedia

References

1. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol. Mar 2004;57(3):225-32. [Medline].

2. Lyos AT. Hürthle Cell Neoplasms of the Thyroid. Baylor College of Medicine. Available at http://www.bcm.edu/oto/grand/21392.html. Accessed October 15, 2009.

3. Bronner MP, Clevenger CV, Edmonds PR, Lowell DM, McFarland MM, LiVolsi VA. Flow cytometric analysis of DNA content in Hürthle cell adenomas and carcinomas of the thyroid. Am J Clin Pathol. Jun 1988;89(6):764-9. [Medline].

4. Pisanu A, Sias L, Uccheddu A. Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment. World J Surg. Aug 2004;28(8):761-5. [Medline].

5. Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP. Hürthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. May 15 2001;19(10):2616-25. [Medline].

6. Maxwell EL, Palme CE, Freeman J. Hürthle cell tumors: applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck Surg. Jan 2006;132(1):54-8. [Medline].

7. Máximo V, Sobrinho-Simões M. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch. Aug 2000;437(2):107-15. [Medline].

8. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, et al. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol. Apr 2007;60(4):377-81. [Medline].

9. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, et al. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol. Apr 2007;60(4):377-81. [Medline].

10. American Cancer Society. Cancer Facts & Figures 2009. American Cancer Society. Available at http://www.cancer.org/downloads/STT/500809web.pdf. Accessed October 2009.

11. Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. Apr 15 2006;106(8):1669-76. [Medline].

12. Cooper DS, Schneyer CR. Follicular and Hürthle cell carcinoma of the thyroid. Endocrinol Metab Clin North Am. Sep 1990;19(3):577-91. [Medline].

13. Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg. Dec 2004;28(12):1266-70. [Medline].

14. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer. May 23 2005;92(10):1892-8. [Medline].

15. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med. Aug 2006;47(8):1260-6. [Medline].

16. Elliott DD, Pitman MB, Bloom L, Faquin WC. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer. Apr 25 2006;108(2):102-9. [Medline].

17. Paphavasit A, Thompson GB, Hay ID, Grant CS, van Heerden JA, Ilstrup DM, et al. Follicular and Hürthle cell thyroid neoplasms. Is frozen-section evaluation worthwhile?. Arch Surg. Jun 1997;132(6):674-8; discussion 678-80. [Medline].

18. Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. Aug 2004;445(2):183-8. [Medline].

19. Fernández CA, Puig-Domingo M, Lomeña F, Estorch M, Camacho Martí V, Bittini AL, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest. Mar 2009;32(3):228-33. [Medline].

20. Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J. Mar 2009;56(1):105-12. [Medline].

21. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL. Is there a role for radiation therapy in the management of Hürthle cell carcinoma?. Int J Radiat Oncol Biol Phys. Jul 15 2003;56(4):1067-72. [Medline].

22. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, et al. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res. Jun 1 2005;65(11):4716-27. [Medline].

23. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res. Jun 1 2006;12(11 Pt 1):3425-34. [Medline].

24. Mills SC, Haq M, Smellie WJ, Harmer C. Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. Mar 2009;35(3):230-4. [Medline].

25. Arganini M, Behar R, Wu TC, Straus F 2nd, McCormick M, DeGroot LJ, et al. Hürthle cell tumors: a twenty-five-year experience. Surgery. Dec 1986;100(6):1108-15. [Medline].

26. Azadian A, Rosen IB, Walfish PG, Asa SL. Management considerations in Hürthle cell carcinoma. Surgery. Oct 1995;118(4):711-4; discussion 714-5. [Medline].

27. Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS, et al. Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?. Ann Surg. Apr 1998;227(4):542-6. [Medline].

28. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab. Feb 2000;85(2):878-82. [Medline].

29. Devita VT, Hellman S, Rosenberg SA. Cancer of the Endocrine System. In: Cancer: Principles and Practice of Oncology. 7th Ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004.

30. Fagin JA. Molecular genetics of tumors of thyroid follicular cells. In: Werner & Ingbar's The Thyroid. Philadelphia, Pa: Lippincott, Williams, & Wilkins; 2000:886-94.

31. Gosain AK, Clark OH. Hürthle cell neoplasms. Malignant potential. Arch Surg. May 1984;119(5):515-9. [Medline].

32. Grant CS. Operative and postoperative management of the patient with follicular and Hürthle cell carcinoma. Do they differ?. Surg Clin North Am. Jun 1995;75(3):395-403. [Medline].

33. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med. Nov 1998;39(11):1903-6. [Medline].

34. Larsen PR, Davies TF, Hay IA. Molecular Pathogenesis (Follicular carcinoma). In: Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders, Co; 1998:490-3.

35. Luna-Ortiz K, Hurtado-Lopez LM, Valderrama-Landaeta JL, Ruiz-Vega A. Thyroglossal duct cyst with papillary carcinoma: what must be done?. Thyroid. May 2004;14(5):363-6. [Medline].

36. Mazzaferri EL. Thyroid cancer in thyroglossal duct remnants: a diagnostic and therapeutic dilemma. Thyroid. May 2004;14(5):335-6. [Medline].

37. McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery. Dec 1996;120(6):1000-4; discussion 1004-5. [Medline].

38. McHenry CR, Sandoval BA. Management of follicular and Hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am. Oct 1998;7(4):893-910. [Medline].

39. Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol. Jun 1996;20(6):686-94. [Medline].

40. Ron E, Schneider AB. Thyroid Cancer. In: Schottenfeld, D Fraumeni J eds. Cancer. Epidemiology and Prevention. 3^rd ed. Oxford University Press: 2006.

41. Rosen IB, Luk S, Katz I. Hürthle cell tumor behavior: dilemma and resolution. Surgery. Oct 1985;98(4):777-83. [Medline].

42. Sanders LE, Silverman M. Follicular and Hurthle cell carcinoma: predicting outcome and directing therapy. Surgery. Dec 1998;124(6):967-74. [Medline].

43. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. Jan 29 1998;338(5):297-306. [Medline].

44. Tallini G. Oncocytic tumours. Virchows Arch. Jul 1998;433(1):5-12. [Medline].

45. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF. Invasive Hürthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc. Dec 1984;59(12):851-5. [Medline].

Further Reading

Keywords

Hürthle cell carcinoma, Hurthle cell carcinoma, thyroid cancer, Ashkenazi cells, oncocytic tumors, oncocytoma, oxyphil tumor, follicular carcinoma oxyphilic type, differentiated thyroid cancer, Hürthle cell neoplasms, follicular carcinoma of the thyroid, follicular cell neoplasms, oncocytic cells, Hashimoto thyroiditis, Hashimoto's thyroiditis, nodular goiter, toxic goiter, thyroid gland, cancer, papillary thyroid carcinoma, PTC

Contributor Information and Disclosures

Author

Serhat Aytug, MD, Staff Physician, Division of Endocrinology, Diabetes and Metabolism, CrystalRun Healthcare
Serhat Aytug, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, Endocrine Society, and Pituitary Society
Disclosure: Nothing to disclose.

Coauthor(s)

Lawrence E Shapiro, MD, Chief, Division of Endocrinology and Metabolism, Professor of Medicine, Department of Medicine, Winthrop University Hospital
Lawrence E Shapiro, MD is a member of the following medical societies: American Diabetes Association, American Thyroid Association, and Endocrine Society
Disclosure: Nothing to disclose.

Medical Editor

Antoni Ribas, MD, Department of Medicine, Division of Hematology-Oncology, Assistant Professor of Medicine, University of California at Los Angeles Medical Center
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

CME Editor

Rajalaxmi McKenna, MD, FACP, Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD, Clinical Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine at Tucson; Consulting Staff, Arizona Cancer Center
Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research
Disclosure: GlobeImmune Salary Consulting; Amplimed Consulting fee Consulting; FibroGen Consulting fee Consulting